Search Results for "Multiple Sclerosis Lundbeck"
Original Source: Lundbeck
Depression, schizophrenia, Alzheimer's, Parkinson's, epilepsy, Multiple Sclerosis, and migraines have their foundation in the Central Nervous System - our key focus areas. Lundbeck's entire R&D efforts to central nervous system (CNS) disorders.
Matching Channels
Multiple sclerosis (MS) is the most common disabling neurological condition affecting 100,000 young adults in the UK. The condition results from autoimmune damage to myelin, causing interference i...
ATX-MS-1467 for patients with multiple sclerosis (MS)
ATX-MS-1467 is a novel treatment that was developed with the aim of working with the immune system to treat the underlying cause of disease rather than just treating the symptoms or suppressing the...
Matching News
H. Lundbeck A/S: Lundbeck elects new chairman
H. Lundbeck A/S (Lundbeck) today announced that its Board of Directors will be electing a new chairman after the annual general meeting to be held on 21 March. Mats Pettersson, member of Lundbeck's...
Vernalis plc and H.Lundbeck A/S Achieve Third Research Milestone
Vernalis plc today announces it has achieved a third milestone in its drug discovery collaboration with H.Lundbeck A/S (Lundbeck). Vernalis will receive a payment of £0.75m from Lundbeck in reco...
Lundbeck plans to establish a more flexible commercial organisation in Europe
H. Lundbeck A/S (Lundbeck) today announced plans to restructure its commercial organisation in Europe. The aim is partly to establish a more flexible commercial infrastructure with respect to detailin...
EpiCast Report: Multiple Sclerosis - Epidemiology Forecast to 2022
EpiCast Report: Multiple Sclerosis - Epidemiology Forecast to 2022 Summary Multiple sclerosis (MS) is an inflammatory disease in which the myelin sheaths around the axons of the brain and spinal cord...
Nanoparticle Halts Multiple Sclerosis in mice
In a breakthrough for nanotechnology and multiple sclerosis, a biodegradable nanoparticle turns out to be the perfect vehicle to stealthily deliver an antigen that tricks the immune system into stoppi...
Lundbeck launches Selincro® in Norway, Finland, Poland and the Baltic countries. Valby, 2013-04-22 08:00 CEST (GLOBE NEWSWIRE) -- H. Lundbeck A/S (Lundbeck) announced that the company shipped Selin.....
ImaginAb, Lundbeck in CNS antibody deal
Antibody company ImaginAb Inc. (Inglewood, Calif.) partnered with H. Lundbeck A/S (CSE:LUN) to reengineer an antibody against an undisclosed CNS target from Lundbeck for in vivo molecular imaging and...
New nanoparticle halts relapsing remitting multiple sclerosis in mouse model
In a breakthrough for nanotechnology and multiple sclerosis, a biodegradable nanoparticle turns out to be the perfect vehicle to stealthily deliver an antigen that tricks the immune system into stoppi...
Matching PubMed Articles
Multiple sclerosis-associated retrovirus and progressive disability of multiple sclerosis.
Retrovirus-like particles containing the multiple sclerosis-associated retrovirus RNA, significantly found in the cerebrospinal fluid of patients with multiple sclerosis, have been preliminarily assoc...
Multiple sclerosis: Is multiple sclerosis caused by venous insufficiency?
The management of multiple sclerosis in children: a European view.
About 3-5% of all patients with multiple sclerosis experience the onset of their disease under the age of 16. A significant proportion of paediatric multiple sclerosis patients develop significant cog...
Background: Multiple sclerosis is a presumed autoimmune disease associated with genetic and environmental risk factors such as infectious mononucleosis. Recent research has shown infectious mononucleo...
Alerting Network Dysfunction in Early Multiple Sclerosis.
The objective of this study is to assess attention in recently diagnosed relapsing-remitting multiple sclerosis patients. Twenty-seven patients with early multiple sclerosis and low clinical disabilit...
